The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

1. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955; 102:157-177.

2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380384.

3. Billingham RE, Brent L, Medawar PW. Quantitative studies on tissue transplantation immunity II: the origin, strength and duration of actively and adoptively acquired immunity. Proc Roy Soc Biol 1954; 143:58-80.

4. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20:1561-1572.

5. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18:769-778.

6. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 1976; 33:241.

7. Borberg H, Oettgen HF, Chondry F, Beattie EJ, Jr. Inhibition of established transplants of chemically induced sarcomas in syngenic mice by lymphocytes from immunized donors. Int J Cancer 1972; 10: 539-547.

8. Smith HG, Harmel RP, Hanna MG, Jr., Zwillig BS, Zbar B, Rapp HJ. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J Natl Cancer Inst 1977; 58:1315-1322.

9. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25:323-388.

10. Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2. J Immunol 1981; 126:1318-1322.

11. Eberlein T, Rosenstein JM, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J Exp Med 1982; 156:385-397.

12. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159:495-507.

13. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-1321.

14. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 1987; 139:295-304.

15. Shu S, Chou T, Rosenberg SA. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Research 1987; 47:1354-1360.

16. Liu J, Finke J, Krauss JC, Shu S, Plautz GE. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules. Cancer Immunol Immunother 1998; 46:268-276.

17. Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, et al. Alterations in NFkB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91:718-721.

18. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999; 48:346-352.

19. Lockhart DC, Chan AK, Mak S, Joo HG, Daust HA, Carritte A, et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor- infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001; 129:749-756.

20. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-685.

21. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147:729-737.

22. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991; 146:4414-4420.

23. Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 1994; 152:1277-1288.

24. Chin CS, Graham LJ, Hamad GG, George KR, Bear HD. Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J Surg Res 2001; 98:108-115.

25. Anderson PM, Blazar BR, Bach FH, Ochoa AC. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity. J Immunol 1989; 142:1383-1394.

26. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49:4770-4774.

27. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987; 79:1067-1075.

28. Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod 1990; 9:149-159.

29. McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science 1995; 268:106-111.

30. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 1996; 56:4338-4342.

31. Tanigawa K, Takeshita N, Craig RA, Phillips K, Knibbs RN, Chang AE, et al. Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites. J Immunol 2001; 167:3089-3098.

32. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001; 182:58-67.

33. Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002; 25:207-217.

34. Sondak VK, Wagner PD, Shu S, Chang AE. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 1991; 126:442-446.

35. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7:11591162.

36. Wahl WL, Sussman JJ, Shu S, Chang AE. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J Immunother 1994; 15:242-250.

37. Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cellular Immunol 1997; 178:24-32.

38. Inoue M, Plautz GE, Shu S. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 1996; 56:4702-4708.

39. Kjaergaard J, Shu S. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol 1999; 163:751-759.

40. Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999; 59:5245-5249.

41. Sussman JJ, Wahl WL, Chang AE, Shu S. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J Immunother 1995; 18:35-44.

42. Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Augmentation vs inhibition: effects of conjunctional 0X-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001; 167:6669-6677.

43. Dillman RO, Hurwitz SR, Schiltz PM, Barth NM, Beutel LD, Nayak SK, et al. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother Radiopharm 1997; 12:65-71.

44. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73:1731-1737.

45. Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J, et al. Histopathologic analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1994; 38:299-303.

46. Kagamu H, Shu S. Purification of L-selectinlow cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998; 160:3444-3452.

47. Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA. Helper-independent, L-selectinlow CD8+ T cells with broad antitumor efficacy are naturally sensitized during tumor progression. J Immunol 2000; 165:5738-5749.

48. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000; 20:17-56.

49. Plautz GE, Mukai S, Cohen PA, Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 2000; 165:3656-3662.

50. Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, et al. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 2001; 21:215-248.

51. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 2000; 165:7116-7124.

52. Winter H, Hu HM, McClain K, Urba WJ, Fox BA. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity vs adoptive immunotherapy. J Immunol 2001; 166:7370-7380.

53. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 1985; 75:67-75.

54. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985; 55:1327-1333.

55. Yang JC, Mule JJ, Rosenberg SA. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J Immunol 1986; 137:715-722.

56. Roberts K, Lotze MT, Rosenberg SA. Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 1987; 47:4366-4371.

57. Mule JJ, Yang J, Shu S, Rosenberg SA. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 1986; 136:3899-3909.

58. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313(23):1485-1492.

59. Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7:477-485.

60. Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991; 9:641-648.

61. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486-498.

62. Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989; 25:S21-S28.

63. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85:622-632.

64. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 1986; 64:743-749.

65. Yoshida S, Tanaka R, Takai N, Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988; 48:50115016.

66. Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF. Intralesional infusion of lympho-kine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 1988; 23:725-732.

67. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840-852.

68. Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 2001; 39:31-42.

69. Kruse CA, Schiltz PM, Bellgrau D, Kong Q, Kleinschmidt-De Masters BK. Intracranial administrations of single of multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 1994; 19:161-168.

70. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45:77-87.

71. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10:535-544.

72. Graham S, Babayan RK, Lamm DL, Sawczuk I, Ross SD, Lavin PT, et al. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Urol 1993; 11:27-34.

73. Lavin PT, Maar R, Franklin M, Ross S, Martin J, Osband ME. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc 1992; 24:3059-3064.

74. Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer 1995; 31A:698-708.

75. Garlie NK, Siebenlist RE, LeFever AV. T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations. J Urol 2001; 166:299-303.

76. Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor vs costimulatory signals. J Immunology 1996; 157:3280-3289.

77. Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP, Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J Immunother 2001; 24:408-419.

78. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163:6292-6300.

79. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97:12198-12203.

80. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-484.

81. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8:631-637.

82. Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon g and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647-658.

83. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996; 65:413421.

84. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159-1166.

85. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12:1475-1483.

86. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000; 23:17-27.

87. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24:363-373.

88. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-854.

89. Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51:4199.

90. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Research 1993; 53:1380-1387.

91. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, et al. Loss of T-cell receptor z chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613-5616.

92. Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldwater N, Gitlitz B, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8 (+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740-745.

93. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521-2529.

94. Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Leveque J, Guille F, et al. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw 2000; 11:217-224.

95. Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, et al. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Cancer Immunol Immunother 1995; 41:293-301.

96. Crannage KE, Rogers K, Jacob G, Stoddard CJ, Thomas WE, Potter CW, et al. Factors influencing the establishment of tumour-infiltrating lymphocyte cultures from human breast carcinoma and colon carcinoma tissue. Eur J Cancer 1991; 27:149-154.

97. Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 1990; 98:259-268.

98. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98:14565-14570.

99. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999; 45:141-157.

100. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15:796-807.

101. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997; 178:101-107.

102. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998; 89:42-51.

103. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000; 6:2209-2218.

104. Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE, et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 1999; 54:617-623.

105. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126:1225-1231.

106. Peng L, Kjaergaard J, Plautz GE, Awad M, Drazba J, Shu S, Cohen PA. Tumor-induced L-seledinhigh suppressor T cells can mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002; 169:4811-4821.

Tumor-Specific Vaccine Development

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment